Vera gains after FDA nod for kidney disease therapy
Seeking Alpha ·
Shares of Vera Therapeutics ( VERA ) jumped on Tuesday after the U.S. Food and Drug Administration approved the company’s kidney disease therapy, atacicept, under its accelerated pathway. According to the FDA, the once-weekly injectable branded as Trutakna will be available in the
DYAX Investor Sentiment
Bullish (Long) 58% · Bearish (Short) 42%
514 participants